(MENAFN- iCrowdNewsWire)
The Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market is estimated to reach over USD 23.06 billion by 2030, exhibiting a CAGR of 19.2% during the forecast period.
Request for Sample Pages:
DNA fragments produced in the bloodstream for critical and chronic illnesses are referred to as circulating cell-free DNA. In recent years, circulating DNA (ctDNA), also known as ccfDNA, has gained prominence as a non-invasive disease indicator. The scientific community's interest in ctDNA therapeutic applications continues to develop at an exponential rate, enhancing its attractiveness as a viable target in a wide range of research disciplines. The growing concern for early cancer detection is one of the key drivers of the Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market. Other drivers include the effectiveness of NIPTs, an increase in cancer prevalence, and an increase in R&D projects to examine the utility of circulating biomarkers in disease diagnosis. Advances in molecular technology are encouraging researchers to look into cfDNA as a potential tool for developing less invasive diagnostics. The adoption of cfDNA-based diagnostics improves clinical decision-making as well as patient outcomes. However, the market expansion is hampered by a lack of standardization, poor reimbursement practices, and legal and regulatory constraints.
List of Prominent Players in the Circulating Cell-Free DNA (ccfDNA) Diagnostics Market:
Hoffmann-La Roche
Natera Inc.
Illumina Inc.
Agena Bioscience
Paragon Genomics
Thermo Fisher Scientific
Bio-Rad Laboratories
Lucence Health
Eurofins
Market Dynamics:
Drivers-
One of the preliminary drivers of the Global Circulating Cell-Free DNA (ccfDNA) Diagnostics Market is the growing concern for early cancer detection. Other drivers include the success of NIPTs, increased cancer prevalence, and increased research and development initiatives to investigate the usefulness of circulating biomarkers in disease diagnosis. More research is needed to develop a consistent approach for analyzing these biomarkers in patients with cardiovascular disease, neurological disorders, and other conditions. This creates potential opportunities for new and rising industry competitors vying for market share in the field.
Challenges:
Other challenges impeding the market's expansion include a shortage of qualified medical practitioners, expensive tests, unaffordability in low-income nations, and ethical concerns over genetic testing. Among the barriers preventing market, expansion are a lack of uniformity, subpar reimbursement procedures, and legal and regulatory limitations. Market expansion is also hampered by the lack of awareness among residents of developing countries.
Regional Trends:
The Circulating Cell-Free DNA (ccfDNA) Diagnostics market in North America is expected to grow significantly, with Canada and the United States making up the majority of its revenue share. Due to these regions' expanding economy, better healthcare systems, and higher rates of disease, Numerous biotechnology and pharmaceutical companies have been lured by the promise of the cell-free DNA testing market to buy other sizable businesses or launch new tests. The cell-free DNA market in this region is being driven by an increase in the prevalence of diseases like chromosomal abnormalities brought on by high maternal age, changing lifestyles, poor dietary habits, and an increase in cancer incidence, as well as an increase in healthcare spending and awareness. This will probably accelerate market expansion across the entire region. Similar to this, increasing healthcare R&D would spur regional market expansion.
Recent Developments:
- In May 2022, Lucene announced the capability of ctDNA and circulating tumour RNA (ctRNA)-based liquid biopsy solution for lung cancer screening at the 2022 ASCO Annual Meeting. These ongoing innovations are anticipated during the projection period to fuel the market growth at a good pace.
- For its recently released ctDNA test Cobas, approved for blood-based genetic tests, Roche Holdings AG received U.S. FDA approval. Roche also made a foray into the NIPT business when it bought Ariosa Diagnostics. For its cutting-edge research in donor-derived Cell-Free DNA tests for kidney and heart transplant recipients, CareDx, Inc. purchased Allenex AB.
Curious about this latest version of the report? Obtain Report Details @
Segmentation of Circulating Cell-Free DNA (ccfDNA) Diagnostics Market-
By Application
- Non-invasive Prenatal Testing
- Cancer Diagnostics
- Others
By End-Use
- Hospitals & Prenatal Clinics
- Diagnostic Centers
- Academic & Government Institutes
- Biotechnology & Pharmaceutical Companies
By Region-
North America-
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
For More Information @
MENAFN06102022003318003403ID1104977314
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.